Numinus CEO Payton Nyquvest On Transforming Healthcare With Psychedelics
5 de mar. de 2023 ·
52m 32s
Descarga y escucha en cualquier lugar
Descarga tus episodios favoritos y disfrútalos, ¡dondequiera que estés! Regístrate o inicia sesión ahora para acceder a la escucha sin conexión.
Descripción
Mental health is perhaps the biggest health issue facing society and traditional medicine has been limited in its success treating it. Psychedelic compounds have been healing people for thousands of...
mostra más
Mental health is perhaps the biggest health issue facing society and traditional medicine has been limited in its success treating it. Psychedelic compounds have been healing people for thousands of years but there are challenges around how to properly service the public. Numinus CEO Payton Nyquvest discusses focusing on profitability and the need for service providers to be able to offer various psychedelic therapies. Possible FDA approval of MDMA this year would be a huge catalyst.
Our links:
The Cannabis Investing Podcast
The Cannabis Investing Podcast provides actionable investment insight and the context with which to understand the burgeoning cannabis industry.
Seeking Alpha Premium
A comprehensive set of features and analysis that helps take the guesswork out of your investing decisions. Get the bottom-line on any stock or ETF with our Premium tools.
Twitter
Instagram
Show links:
Numinus website
Numinus IG
Numinus Twitter
mostra menos
Our links:
The Cannabis Investing Podcast
The Cannabis Investing Podcast provides actionable investment insight and the context with which to understand the burgeoning cannabis industry.
Seeking Alpha Premium
A comprehensive set of features and analysis that helps take the guesswork out of your investing decisions. Get the bottom-line on any stock or ETF with our Premium tools.
Show links:
Numinus website
Numinus IG
Numinus Twitter
Información
| Autor | Seeking Alpha |
| Organización | Seeking Alpha |
| Página web | seekingalpha.com |
| Etiquetas |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Comentarios